TxCell Receives US Patent For Ovasave To Treat IBD

TxCell Receives US Patent For Ovasave To Treat IBD
Tx CellsA key patent was recently granted by the United States Patent and Trademark Office (USPTO) to TxCell SA for its lead product Ovasave® to address inflammatory bowel disease (IBD). The patent will protect Ovasave until 2030. TxCell SA is a biotechnology company committed to developing cost-effective, innovative and personalized T-cell immunotherapies through the utilization of antigen specific regulatory T-cells (Ag-Tregs) that might address the unmet needs of autoimmune and severe chronic inflammatory diseases. Ovasave is now being assessed in a placebo-controlled, multi-national, phase 2b trial for refractory Crohn’s disease. This patent is the most recent asset for TxCell as it protects a very promising method to assess treatment for intestinal IBD through the company Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg), a personalized T cell immunotherapy candidate. In Russia, the equivalent patent has already been granted. Other applications for patents concerning Ovasave to address IBD are pending in global major markets. TxCell actually controls or owns over 140 patents within in the field of antigen-specific Treg (Ag-Treg) cell-based therapy. These patents provide l
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *